Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101

NCT02008539 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
13
Enrollment
INDUSTRY
Sponsor class

Stopped Enrollment terminated after 13 patients (14 planned); further patients did not meet eligibility criteria to receive autologous IMP

Conditions

Interventions

Sponsor

Apceth GmbH & Co. KG